Stockwinners Market Radar for April 01, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EDT Cathie Wood's ARK Investment bought 273K shares of PacBio today

20:17 EDT Cathie Wood's ARK Investment bought 172K shares of SoFi Technologies today

19:50 EDT 22nd Century trading halted, news pending

19:50 EDT EMCORE trading halted, news pending

19:50 EDT Tritium DCFC trading halted, news pending

18:40 EDT Broadcom exec Brazeal sells 2,500 common shares - In a regulatory filing, Broadcom chief legal and corporate affairs officer Mark David Brazeal disclosed the sale of 2,500 common shares of the company on March 28 at a price of $1,318.975 per share.

18:11 EDT Copart chairman sells $34.7M in common stock - In a regulatory filing, Copart disclosed that its chairman Jayson Adair sold 600K shares of common stock on March 28th in a total transaction size of $34.7M.

17:31 EDT TotalEnergies SE buys $4.5M in Clearway Energy common stock - In a regulatory filing, Clearway Energy disclosed that shareholder TotalEnergies SE bought 196.7K shares of the company's common stock, boosting its stake by $4.5M. Shares of Clearway Energy are up 2.2% afterhours at $23.57.

17:24 EDT Kidpik, Nina Footwear enter definitive merger agreement - Kidpik and Nina Footwear, a private company operating a brand specializing in women's and kids' dress shoes and accessories for special occasions, announced that they have entered into a definitive merger agreement. The Board of Directors of both companies have approved the all-stock transaction. The combined company will operate as Nina Holdings Corp. In connection with the merger, Nina Footwear stockholders will be issued shares of common stock of Kidpik such that upon closing thereof, Nina Footwear's stockholders will own 80% of Kidpik's outstanding common stock. Kidpik is controlled by Ezra Dabah, the CEO, Chairman, and majority stockholder (67% beneficial owner) of Kidpik, who is also the CEO of Nina Footwear. Dabah and his children own approximately 79.3% of Nina Footwear, and Dabah and his extended family own 100% of Nina Footwear. Dabah, his children and wife are expected to continue to control approximately 76.8% of the combined company's voting shares following the closing of the merger. Kidpik's entry into the merger agreement was approved by the Kidpik Board of Directors, acting on the unanimous recommendation of a special committee consisting of independent and disinterested directors of Kidpik that was formed to negotiate and evaluate a potential strategic transaction involving Kidpik. According to the terms of the merger agreement, Kidpik will acquire Nina Footwear through a reverse subsidiary merger that is intended to be a tax-free reorganization. Upon closing of the merger, the combined company will be renamed "Nina Holding Corp." and its symbol will change to "NINA". There is not expected to be any change in Kidpik's officers or directors as a result of the transaction. There are also a number of related party transactions between Nina Footwear and Kidpik as disclosed in Kidpik's filings with the SEC, which are expected to be extinguished as a result of the merger. The closing of the transaction is subject to customary closing conditions, including the preparation and mailing of a proxy statement by Kidpik, and the receipt of required stockholder approvals from Kidpik and Nina Footwear stockholders, and is expected to close in the third quarter of 2024.

17:17 EDT Boeing awarded $116.7M Army contract - Boeing was awarded a $116.7M hybrid contract for Apache logistics support. Bids were solicited via the internet with one received. Work has an estimated completion date of April 30, 2025. FY24 Army working capital funds in the amount of $116.7M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:09 EDT General Motors exec Johnson sells 27,122 common shares - In a regulatory filing, General Motors executive VP Gerald Johnson disclosed the sale of 27,122 common shares of the company on March 28 at a price of $45.26 per share.

17:03 EDT Mind Medicine announces voluntary delisting from Cboe Canada - Mind Medicine announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed's common shares will continue to be listed and tradable on The Nasdaq Global Select Market under the symbol "MNMD" and Canadian shareholders can continue to trade their shares on Nasdaq. The Company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing. MindMed's Nasdaq listing provides its shareholders with sufficient liquidity, as Nasdaq accounts for approximately 95% of its trading volume. The substantial savings in exchange fees, legal fees, and managerial time and effort to maintain a dual listing can be redirected to initiatives intended to generate shareholder value. The board of directors of the Company has approved the voluntary delisting from Cboe Canada. In accordance with the Cboe Canada Listing Manual, Cboe Canada does not require shareholder approval of the voluntary delisting of MindMed's common shares, as an acceptable alternative market will exist for the common shares on the date of delisting. Following delisting from Cboe Canada, MindMed's shareholders can trade their common shares through their brokers on Nasdaq.

17:00 EDT Vail Resorts names Courtney Goldstein CMO - Vail Resorts announced that Courtney Goldstein has been appointed executive vice president and chief marketing officer, effective April 29, 2024. Goldstein joins the company with more than two decades of experience at Comcast and American Express. Goldstein will report to CEO Kirsten Lynch and join the company's executive team. "Courtney has a proven track record of growing subscription business models by leveraging data and technology," said Kirsten Lynch, chief executive officer of Vail Resorts. "Her leadership and experience will be valuable as our company continues to grow the Epic Pass subscription model, launches an innovative new gear membership business, My Epic Gear, and innovates the guest experience through digital technology such as Mobile Pass and My Epic Assistant in the My Epic app."

16:41 EDT Lifeward CEO updates shareholders on Exoskeleton and Medicare progress - "As we communicated in Lifeward's March 1 press release, a final payment rate for exoskeletons was deferred in CMS' Healthcare Common Procedure Coding System final determination released on February 29, so the agency could obtain more information about pricing for our latest generation exoskeleton. As a result of the deferral, the payment rate is not included in CMS' April 2024 Durable Medical Equipment, Prosthetics, Orthotics and Supplies fee schedule of Medicare payment rates that are effective April 1. Since the HCPCS final determination was released, we have worked very closely with the agency to review the invoice and transaction information that we had previously submitted and provide supplemental data or explanations as additional questions arise. While the latest development is a temporary delay, we are encouraged that CMS has indicated to us that once it determines a final payment rate, the agency can amend the April 2024 DMEPOS fee schedule so that the payment rate for exoskeletons can be established for the rest of 2024. This is important because it means that the establishment of a payment rate does not need to be delayed until the next HCPCS cycle six months from now. Our active engagement with CMS is ongoing and we work to establish the payment rate as soon as possible. Until a payment rate for exoskeletons is added to the DMEPOS schedule, the Medicare Administrative Contractors still have authority to approve and pay claims on a case-by-case basis with discretion to set the payment rate. As we discussed on our Q4'23 earnings call, we have submitted 35 Medicare claims for payment which are eligible for reimbursement under the existing authority of the MACs. So far, one claim has been paid with the remaining ones in various stages of the claim review process. Lifeward intends to submit an additional 60-75 additional Medicare claims by the end of 2024 to accelerate its momentum in expanding access for qualified Medicare beneficiaries."

16:35 EDT CMS finalizes payment update for 2025 Medicare Advantage, sees payments up 3.7% - The Centers for Medicare & Medicaid Services announces: "Today, the Centers for Medicare & Medicaid Services, or CMS, finalized the Calendar Year (CY) 2025 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug (Part D) Programs that updates payment policies for these programs and ensures payment accuracy. The Rate Announcement complements policies in the CY 2025 MA and Part D proposed rule that would strengthen protections for the millions of people who rely on MA and Medicare Part D prescription drug coverage, which will be finalized in the coming days. Under this CY 2025 Rate Announcement, payments from the government to MA plans are expected to increase on average by 3.70 percent, or over $16 billion, from 2024 to 2025. The federal government is projected to pay between $500 and $600 billion in Medicare Advantage payments to private health plans in 2025. CMS is also finalizing improvements to the structure of the Medicare Part D drug benefit for CY 2025 that will result in lower drug costs for millions of people with Medicare through the concurrent release of the Final CY 2025 Part D Redesign Program Instructions. Thanks to the Inflation Reduction Act, President Biden's lower-cost prescription drug law, annual out-of-pocket costs will be capped at $2,000 for people with Medicare Part D in 2025, leading to even more savings for people with Medicare Part D in CY 2025. The Rate Announcement finalizes annual updates to MA payment growth rates and changes to the MA and Part D payment methodologies to improve payment accuracy. The finalized CY 2025 Rate Announcement incorporates the most recent available fee-for-service payment data through quarter 4 of 2023 and includes the continued phase-in of the updated MA risk adjustment model that was first implemented in 2024 and continued phase-in of updates to the calculation of growth rates related to medical education costs, as well as other technical improvements. Last year, CMS finalized CY 2024 technical and clinical updates to the MA risk adjustment model to keep it up-to-date and improve payment accuracy, as well as updates to the calculation of growth rates to better account for medical education costs. For 2024, MA offerings for people with Medicare remained stable-including premiums, supplemental benefits, and choice." Among the publicly traded companies in the space impacted by the announcement are Humana (HUM), Cigna (CI), Agilon Health (AGL), CVS Health (CVS), and Alignment Healthcare, Inc. (ALHC), shares of which are all trading lower afterhours. Reference Link

16:31 EDT Transocean announces $195M deepwater drillship contract - Transocean announced a 365-day contract extension for the Deepwater Asgard with an independent operator in the U.S. Gulf of Mexico. The program is expected to commence in June in direct continuation of the rig's current program and includes additional services. The total contract value of approximately $195M includes a $10.9M lump sum payment, which is not included in the estimated backlog of approximately $184M.

16:29 EDT Supreme Court of Florida approves marijuana measure for November ballot - The Supreme Court of Florida approved this afternoon that a measure to legalize adult-use marijuana in the state will be allowed on the November ballot. "A ballot initiative to legalize the recreational use of marijuana under Florida law obtained the required number of signatures to trigger mandatory judicial review of the initiative's validity. Our role is narrow-we assess only whether the amendment conforms to the constitutionally mandated single-subject requirement, whether the ballot summary meets the statutory standard for clarity, and whether the amendment is facially invalid under the federal constitution. In light of those limited considerations, we approve the proposed amendment for placement on the ballot," the court said in an opinion. Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).

16:25 EDT SKYX Platforms management sees 'accelerated cadence of sales' - "Our year ended December 31 was highlighted by our first two full quarters of significant revenue, including sales and rollout of our advanced ceiling smart and standard plug & play platform products on many leading U.S. and Canadian websites. We believe we have accelerated our cadence of sales with a robust gross margin profile, notably managing the cash burn of SKYX. Our e-commerce platform with over 60 websites is expected to provide additional cash flow to the Company, which, when combined with our existing cash, we anticipate will be sufficient for 18 months of operations. Management anticipates that the Company will become cash flow positive during 2025. We are encouraged with our path to the builder/commercial segments, large online and brick-and-mortar retail partners, as well as to realizing incremental licensing, subscription, and data aggregation revenue that we believe will assist in paving the way for our standardization efforts. Additionally, our e-commerce website platform continues to enhance the acceleration of marketing, distribution channels, collaborations, and sales to both professional and retail segments," said company management.

16:22 EDT PVH Corp. falls 16% to $117.00 after Q4 results, below-consensus guidance

16:19 EDT Veeva CFO Brent Bowman to leave company - According to a regulatory filing, on March 28, 2024, Veeva Systems and Brent Bowman established, via mutual agreement, that Bowman's tenure as Chief Financial Officer and Principal Financial Officer will end as of the close of business on April 1, 2024. Bowman will remain a Veeva employee for three months to ensure a smooth transition. Tim Cabral, the Company's CFO from 2010 to 2020 and a current member of Veeva's board of directors, will serve as Interim CFO and PFO until a replacement is named. A copy of Cabral's biography is available in Veeva's definitive proxy statement, filed with the Securities and Exchange Commission on May 10, 2023, and is hereby incorporated by reference. In connection with Mr. Bowman's departure, his equity grant from the fiscal year ending January 31, 2023 of 10,000 RSUs and 20,000 stock options scheduled to vest on April 1, 2026 will vest as to 9/16th of the RSUs and options on July 1, 2024. Veeva appreciates Bowman's valuable contributions over his nearly four years of service. The change is not the result of any misconduct, any disagreements between Bowman and Veeva about Veeva's financial results or Veeva's accounting principles, practices, and controls, or any issues related to Veeva's operations, policies, or practices. There is no arrangement or understanding between Mr. Cabral and Veeva pursuant to which Mr. Cabral was appointed as Veeva's Interim CFO and PFO.

16:16 EDT Rocket Lab prepares to launch mission for KAIST and NASA - Rocket Lab USA announced it has set the launch window for its next Electron launch. The 'Beginning Of The Swarm' mission is scheduled to launch from Rocket Lab Launch Complex 1 in Mahia, New Zealand during a 14-day launch window that opens on April 24th. Electron will carry two satellites for two separate customers: NEONSAT-1, an Earth observation satellite for the Satellite Technology Research Center at the Korea Advanced Institute of Science and Technology, and NASA's Advanced Composite Solar Sail System. The primary payload for this mission, NEONSAT-1, is an Earth observation satellite with a high-resolution optical camera designed to monitor for natural disasters along the Korean Peninsula by pairing its images with artificial intelligence. NEONSAT-1 is the first satellite developed under the NEONSAT program by SaTReC and KAIST, Korea's leading university in science and technology, which developed and operated Korea's very first satellite KITSAT-1 more than 30 years ago. Other NEONSAT satellites are planned to be launched in 2026 and 2027 to build out the NEONSAT constellation. The program is a collaboration across multiple Korean academic, industry, and research institutions including SaTReC in KAIST, which is leading the program's system design and engineering; the SaTReC Initiative, a Korean satellite manufacturer that has successfully developed seven previous remote sensing satellites for low Earth orbit; and the Korea Aerospace Research Institute, which is managing the mission's ground segments and technology supervision for the NEONSAT program. NEONSAT is funded by the Koren government's Ministry of Science and ICT.

16:09 EDT Duos Technologies' Group company's contracts in backlog $6.6M in revenue - At the end of 2023, the company's contracts in backlog represented approximately $6.6M in revenue, of which approximately $4.4M is expected to be recognized in calendar 2024 not including an estimated $6.0 - $7.0 Min expected near-term awards and renewals. The balance of contract backlog is comprised of multi-year service and software agreements as well as project revenues spanning through fiscal 2024. In the fourth quarter of 2023 the Company withdrew its previously issued guidance due to unforeseen delays from three major projects which delayed recognition of a substantial portion of expected revenues into 2024. Duos expects an improvement in operating results to be reflected over the course of the full year 2024 from the realization of these projects and other anticipated new projects. As a result of typical business seasonality as well as timing and other factors, the Company expects revenues in the first quarter of 2024 to be similar to the fourth quarter of 2023 before sequentially increasing throughout the remainder of the year.

16:06 EDT Arrowroot Acquisition shareholders approve iLearningEngines combination - Arrowroot Acquisition Corp. and iLearningEngines, a player in AI-powered learning automation and information intelligence for corporate and educational use, announced that Arrowroot's shareholders voted to approve the previously announced business combination between Arrowroot and iLearningEngines, at the special meeting of Arrowroot's shareholders held on April 1, 2024. Voters representing over 97% of the issued and outstanding shares of Arrowroot were cast in favor of the proposal in connection with the Business Combination at the Special Meeting. Arrowroot shareholders also voted to approve all other proposals presented at the meeting. Arrowroot plans to file the results of the Special Meeting, as tabulated by the inspector of elections, with the Securities and Exchange Commission on a Current Report on Form 8-K. Upon closing of the Business Combination, which is expected following the satisfaction or waiver of all closing conditions, the combined company intends to operate as iLearningEngines, Inc. and is expected to be listed on Nasdaq under the ticker symbol "AILE", with warrants under the ticker "AILEW". The Nasdaq listing is subject to the closing of the Business Combination and fulfillment of all Nasdaq listing requirements.

16:01 EDT Acorda Therapeutics cancels Q4 earnings conference call - Acorda Therapeutics announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023.

15:01 EDT GCT Semiconductor Holding Inc trading halted, volatility trading pause

14:09 EDT Serina Therapeutics Inc trading halted, volatility trading pause

13:16 EDT Trump Media sinks after disclosing $4M in sales, $58M loss for 2023 - Shares of Trump Media & Technology Group are sinking after a filing this morning revealed the company's sales totaled just $4.1M in 2023. Trump Media posted a loss of ($59.19M) for the year. The filing also revealed that Digital World's financial statements as of December 31, 2023 and 2022, contained an explanatory paragraph relating to substantial doubt about the ability of Digital World to continue as a going concern. Digital World is the special purpose acquisition company that took Trump Media public through a merger. Shares of Trump Media are down 26%, or $16.19, to $45.77 in afternoon trading. Reference Link

12:51 EDT FedEx falls after announcing end of Postal Service agreement - FedEx this morning announced the agreement between FedEx Express and the United States Postal Service for domestic transportation services will expire by its terms on September 29. This decision was made on March 29 "following extensive discussions." The company added, "FedEx and the United States Postal Service have had a long and productive relationship for more than 20 years. Over time, our respective strategies have shifted as we transform our networks and operations for the future. We have long said we would extend the contract with the USPS if we could agree to commercial terms in the best interests of FedEx shareholders. Although we were unable to reach mutually agreeable terms, we remain committed to delivering outstanding service through the completion of our contract in September." Upon the conclusion of the contract, FedEx will implement adjustments to its network "that will drive efficiencies and create more flexibility." The elimination of structural costs currently in place to support postal service volume "will be addressed and, in conjunction with our DRIVE efforts, FedEx profitability will improve in FY25 and beyond," the company noted. Shares of FedEx are down 3% to $280.95 in midday trading.

12:35 EDT Nuvei to be taken private by Advent International for $34.00 per share - Nuvei has entered into a definitive arrangement agreement to be taken private by Advent International, with the support of each of the Company's holders of multiple voting shares, being Philip Fayer, certain investment funds managed by Novacap Management and CDPQ, via an all-cash transaction which values Nuvei at an enterprise value of approximately $6.3B. The Company will continue to be based in Montreal. Nuvei's global reach extends to more than 200 markets across the globe, with local acquiring in 50 markets and connectivity to 680 local and alternative payment methods. In its recent 2023 annual financial statements Nuvei announced that it had processed more than $200B in Total volume, and $1.2B in revenue. Advent is a longstanding investor in the payments space. Nuvei will benefit from the significant resources, operational, and sector expertise, as well as the capacity for investment provided by Advent. Philip Fayer will remain Nuvei's Chair and CEO and will lead the business in all aspects of its operations. Nuvei's current leadership team will also continue following the conclusion of the transaction. Advent will acquire all the issued and outstanding subordinate voting shares of Nuvei and any Multiple Voting Shares that are not Rollover Shares. These Subordinate Voting Shares and Multiple Voting Shares will each be acquired for a price of $34.00 per Share, in cash. This price represents a premium of approximately 56% to the closing price of the Subordinate Voting Shares on the Nasdaq Global Select Market on March 15, 2024, the last trading day prior to media reports concerning a potential transaction involving the Company and a premium of approximately 48% to the 90-day volume weighted average trading price per Subordinate Voting Share as of such date. Philip Fayer, Novacap and CDPQ have agreed to roll approximately 95%, 65% and 75%, respectively, of their Shares and are expected to receive in aggregate approximately $560 million in cash for the Shares sold on closing. Philip Fayer, Novacap and CDPQ are expected to indirectly own or control approximately 24%, 18% and 12%, respectively, of the equity in the resulting private company. The proposed transaction has the support of each of the holders of Multiple Voting Shares, namely Philip Fayer, Novacap and CDPQ, who collectively represent approximately 92% of the voting power attached to all the Shares. Nuvei's Board of Directors, after receiving advice from the Company's financial advisor and outside legal counsel, is unanimously recommending that the Nuvei shareholders vote in favour of the transaction. This recommendation follows the unanimous recommendation of a special committee of the Board of Directors which is comprised solely of independent directors and was formed in connection with the transaction. The Special Committee was advised by independent legal counsel and retained TD Securities as financial advisor and independent valuator.

12:13 EDT Universal Health falls after subsidiary hit with $535M jury verdict - Pavilion Behavioral Health System, an indirect subsidiary of Universal Health Services, is a defendant in a lawsuit filed in Champaign County, Illinois, relating to the sexual assault of one minor patient by another minor patient in 2020. The plaintiff asserted claims of negligence and misrepresentation, Universal Health disclosed earlier in a regulatory filing. The case went to trial in March and on March 28, a jury awarded the plaintiff compensatory damages of $60M and punitive damages of $475M. "Based on a search of verdicts in comparable cases, the magnitude of this verdict was unexpected and is unprecedented for a single-plaintiff injury case of this type in Champaign County, Illinois. The Pavilion is evaluating all legal options and intends to challenge this verdict in post-judgment trial court proceedings and on appeal," according to Universal Health. "While the Pavilion has professional liability insurance to cover a portion of these amounts, the final resolution of this case may have a material adverse effect on the Company," it added. Shares of Universal Health are down 5% to $173.18 in midday trading.

12:00 EDT 3M falls -12.9% - 3M is down -12.9%, or -$13.69 to $92.38.

12:00 EDT Coeur Mining rises 10.3% - Coeur Mining is up 10.3%, or 39c to $4.16.

12:00 EDT Doma Holdings rises 34.1% - Doma Holdings is up 34.1%, or $1.55 to $6.09.

11:10 EDT Binah Capital Group Inc trading resumes

11:05 EDT Binah Capital Group Inc trading halted, volatility trading pause

11:00 EDT OneMain completes acquisition of Foursight Capital LLC - OneMain Holdings announced that it has completed its previously announced acquisition of Foursight Capital LLC. Foursight's team, technology, credit models, dealer network and loan portfolio will support OneMain's expansion into the auto lending business.

10:46 EDT Shimmick Corp trading halted, volatility trading pause

10:23 EDT Eiger BioPharmaceuticals sinks 35% to $3.26 after filing Chapter 11 bankruptcy

10:19 EDT NewtekOne hires Taylor Quinn as CRO - NewtekOne has hired Mr. Taylor Quinn as Senior Vice President, Chief Risk Officer for NewtekOne and Newtek Bank, N.A., effective today. Most recently, Taylor was the Senior Vice President, Chief Audit Executive at Amalgamated Bank.

10:13 EDT Eiger BioPharmaceuticals trading resumes

10:08 EDT Saia, Fletes Mexico announce cross-border partnership - Saia Inc. announced an exclusive partnership between Saia LTL Freight and Fletes Mexico via their less-than-truckload division, Carga Express, to serve both companies' U.S. to Mexico cross-border customers. As a result of the partnership, Saia will service Carga Express' shipments entering the U.S. and Carga Express will service Saia's freight entering Mexico. "We are excited about this new partnership with Carga Express as our companies share similar values when it comes to providing efficient, on-time transportation solutions for customers," said Saia Vice President of International Juan Barroso.

10:03 EDT Conifer Holdings enters partnership with Palomar - Conifer Holdings (CNFR) recently launched a strategic partnership with Palomar Holdings, Inc. (PLMR) aimed at providing comprehensive coverage tailored specifically for the cannabis industry on Palomar Specialty Insurance Company and Palomar Excess and Surplus Insurance Company paper. PSIC and PESIC have a financial strength rating of "A-" from A.M. Best. In response to the rapidly evolving landscape of cannabis legalization and the burgeoning needs of cannabis businesses, this partnership represents a significant step forward in addressing the unique risks faced by cannabis entrepreneurs and cultivators.

10:02 EDT CHARGE!, ABC owned TV stations enter into network affiliation agreement - Sinclair Broadcast Group, a subsidiary of Sinclair Inc., announced a new broadcast affiliate distribution agreement with ABC Owned Television Stations that will make CHARGE!, one of Sinclair's free, over-the-air, national broadcast TV networks, available on ABC Owned Television Stations' Diginet 3. CHARGE!'s move into the big 4 network channel positions in the country's largest markets, adds over four million new, over-the-air TV households as well as 3.73 million new pay TV/cable households. "We are thrilled to launch CHARGE! and broaden our partnership with ABC Owned Television Stations. Sinclair continues to grow our multicast networks and securing big- 4 network row positioning for the launch of CHARGE! on all eight ABC powerhouse stations was a key strategic initiative," said Lee Schlazer, SVP, of Distribution.

10:00 EDT Nuscale Power rises 12.8% - Nuscale Power is up 12.8%, or 68c to $5.99.

10:00 EDT GCT Semiconductor falls -9.3% - GCT Semiconductor is down -9.3%, or -$3.08 to $29.98.

10:00 EDT 3M falls -16.3% - 3M is down -16.3%, or -$17.27 to $88.80.

09:49 EDT Macau reports March casino revenue up 53% to 19.5B patacas - Macau's gaming bureau reported March gross revenue from games of fortune in the region was up 53% year-over-year to 19.5B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

09:47 EDT GCT Semiconductor falls -9.4% - GCT Semiconductor is down -9.4%, or -$3.11 to $29.95.

09:47 EDT 3M falls -14.5% - 3M is down -14.5%, or -$15.41 to $90.66.

09:47 EDT Torrid rises 21.2% - Torrid is up 21.2%, or $1.03 to $5.92.

09:43 EDT Keyarch Acquisition Corp trading halted, volatility trading pause

09:36 EDT Nuvei trading halted, news pending

09:30 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:20 EDT Terreno Realty acquires industrial property in Washington for $11M - Terreno Realty sold an industrial property located in Seattle, Washington for a sale price of approximately $11M. The property consists of a 25,000 square foot industrial distribution building on 1.5 acres which is 100% leased to one tenant. The property was purchased by Terreno Realty Corporation on May 6, 2016 for approximately $4.7 million. The unleveraged internal rate of return generated by the investment was 16.5%.

09:12 EDT CXApp enters partnership with Google Cloud - CXApp announced the signing of strategic partnership and development agreements with Google Cloud as part of the launch of the CXAI Platform. The company said, "We are pleased to announce the following strategic initiatives with the Google Cloud team as we make progress on our journey to shape the future of work: 1. AI Partnership a. CXAI Platform Our AI-native platform is built upon our mobile-first, cloud-first Work SuperApp. The Work SuperApp provides a full-stack solution that allows employees to experience all their work tools in a single application. We provide our customer's employees with a simplified immersive user interface, natural language processing inputs, and the assistants to digitally navigate and automate their workday - all seamlessly from anywhere, creating a more human-centric work model. Our state-of-the-art CXAI technology platform is based on 37 filed patents, with 17 of them already granted. This substantial intellectual property not only establishes our company as a technological frontrunner but also secures our position as a pioneer in the industry. a. Our AI tools and models are being built on the strong foundation of our full stack software solution that provides contextual awareness using indoor mapping and on-device positioning technology as well as the data collection of millions of data points from our enterprise app. This new area of spatial intelligence creates the opportunity to personalize the workplace experience at the same time as redefine the workplace environment. b. Generative AI On the CXAI platform we are developing category-leading horizontal and vertical Generative AI applications. Google is partnering with us in enabling these applications with many of their new technologies including the Vertex AI platform. We believe these AI-native applications will become the norm for the new knowledge economy and generate transformational employee experiences everywhere. c. Experiential Analytics The key output of our AI applications is a data and analytics engine that fuses the user, space, and things data to create what we are calling "Experience Analytics".These are the key insights and outcomes that will drive the help solve the future of work problems. 2. Google Cloud and Modernization of SaaS Infrastructure a. Google Cloud powers most of CXApp's enterprise customer applications today and is a natural partner as we expand into advancement of our service offerings. b. As part of our agreement, Google and its service partners will provide advanced services including end-to-end security, analytics and monitoring as well as usage-based SaaS performance enhancements to create the best-in-class cloud-mobile experience for our clients on the new CXAI Platform. c. The first deployment of the CXAI Platform is expected to be in the summer, subject to successful testing and validation with a major new client. d. CXAI's strategy of 'land & expand' also continues to be a key contributor to growing subscription revenues with our existing customer base and the addition of more tailored SaaS offerings will further increase our revenue base. 3. CXAI on Google Marketplace a. Google has agreed to add the CXAI application platform to the Google Marketplace and signed a go-to-market partnership agreement. Google Cloud's sales and marketing teams will work with CXAI on targeting key clients and providing them the best workplace platform experience. b. This is a big step in enabling all of Google's existing clients to have access to the CXAI platform with seamless and automated delivery. c. This will also allow a more standardized offering of our solutions available to a larger customer base expanding our total addressable market."

09:08 EDT Biomea Fusion highlights initial data from type 1 patients dosed with BMF-219 - Biomea Fusion announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study. Case Study Patient 1 Highlights: A 58-year-old, diagnosed with type 1 diabetes 3 years ago; BMF-219 200 mg once-daily; Week 4: Fasting C-peptide increased by 57% compared to Baseline. During a mixed-meal tolerance test the C-Peptide Index increased by 12%. The C-peptide index is the ratio of serum C-peptide to plasma glucose levels and is used to evaluate beta-cell function; Week 8: Fasting C-peptide increased by 80% compared to Baseline. During a MMTT, C-peptide increased up to 200%. The C-Peptide Index (AUC) increased by 40% compared to Baseline; Data on any changes in daily insulin usage are pending. Case Study Patient 2 Highlights: A 24-year-old, diagnosed with type 1 diabetes 7 years ago; BMF-219 100 mg once-daily; Week 4: Fasting C-peptide increased by 16% compared to Baseline. During a MMTT the C-peptide Index increased by 30%; Patient had a near-normal glucose response during the MMTT without receiving any meal-time insulin; Patient had a reduction in daily insulin usage during the first four weeks of the study.

09:06 EDT Abercrombie & Fitch celebrates new 'A&F Wedding Shop' - Abercrombie & Fitch, a division of Abercrombie & Fitch (ANF), celebrated its new "A&F Wedding Shop" collection and rang in wedding season with an immersive and experiential event on March 27, 2024. Partnering with Pinterest (PINS) to bring the latest wedding trends to life, Abercrombie transformed the grounds and rooms of Los Angeles' famed Goldwyn House to highlight pieces from the brand's 100+ piece collection. "The A&F Wedding Shop is designed to outfit our customers for every moment of the multi-faceted wedding experience," said Megan Brophy, Abercrombie & Fitch Co.'s VP of Brand & Experience Marketing. "Nobody plans a wedding without Pinterest, so it was only natural to partner with them to bring the modern wedding story to life."

09:04 EDT Spectral AI appoints Sparks as Chief Commercialization Officer - Spectral AI announced the appointment of Jeremiah Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.

09:02 EDT Abbott announces FDA clearance of i-STAT TBI cartridge - Abbott's i-STAT TBI cartridge has received clearance from the U.S. FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing. This new clearance will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments including urgent care clinics with a certificate to perform moderate complexity tests. This is an important step toward a future where testing could be done outside traditional healthcare settings, such as on the sidelines of sporting events.

09:02 EDT Movella files Form 25 to voluntarily delist from Nasdaq Stock Market - Movella Holdings filed a Form 25 with the Securities and Exchange Commission to voluntarily delist its shares of common stock and warrants, each exercisable for one share of common stock at an exercise price of $11.50 per share from trading on The Nasdaq Stock Market in connection with its previously announced plan to delist the Company's Securities from trading on Nasdaq. The Company expects that trading will be suspended on April 2, 2024 prior to the market opening and that the delisting will occur ten days after the filing of Form 25. Following the delisting, any trading in the Securities would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company expects to have its Securities quoted on a market operated by OTC Markets Group around or after April 12th so that a trading market may continue to exist for the Securities. There is no assurance, however, that a broker will continue to make a market in the Securities or that trading thereof will continue on an OTC market or otherwise.

09:01 EDT First Busey finalizes acquisition of Merchants and Manufacturers - First Busey Corporation announced the completion of its acquisition of Merchants and Manufacturers Bank Corporation, the holding company for Merchants and Manufacturers Bank, effective April 1, 2024. The transaction was previously announced on November 27, 2023. At the effective time of the merger, each share of M&M common stock converted to the right to receive, at the election of each shareholder, and subject to proration and adjustment as provided in the merger agreement, $117.74 in cash, 5.7294 shares of Busey common stock, or mixed consideration of $34.55 in cash and 4.0481 shares of Busey common stock, with total consideration consisting of approximately $12.2 million in cash and 1,429,324 shares of Busey common stock. Busey will operate M&M Bank as a separate banking subsidiary of Busey until it is merged with Busey Bank, which is expected to occur in June 2024. Busey Chairman, President and Chief Executive Officer Van A. Dukeman said, "Through this partnership, Busey and M&M will advance our community banking culture through our shared, longstanding commitments to supporting our associates, customers and communities. Our combined franchise benefits our clients through enhanced capabilities and products, including M&M's Life Equity Loan product, while a growing, dynamic organization presents more professional growth opportunities for associates."

08:56 EDT Kodiak Gas Services completes acquisition of CSI Compressco - Kodiak Gas Services (KGS) announced that it has completed its acquisition of CSI Compressco LP (CCLP), creating the industry's largest contract compression fleet. CSI Compressco units will no longer be publicly traded on the NASDAQ effective as of close of trading on April 1. Kodiak shares will continue to trade on the New York Stock Exchange.

08:52 EDT Jacobs names Kevin Berryman as interim CFO, succeeding Claudia Jaramillo - Jacobs Solutions announced that Kevin Berryman, previously President and CFO and currently Special Advisor to Jacobs' CEO Officer Bob Pragada, has been appointed interim CFO, effective March 29. Berryman succeeds Claudia Jaramillo who is departing the company to pursue other opportunities. Jacobs has initiated a search for a permanent CFO with the assistance of an executive search firm.

08:48 EDT Wearable Devices signs reseller agreement with WisePlus - Wearable Devices announced the signing of a reseller agreement with WisePlus, a premier provider of device software solutions. This collaboration aims to scale the Company's licensing program reach by enabling local, on-site support and customization for enterprises in the markets of South Korea and China, tapping into WisePlus' extensive network and expertise in these regions. Under the terms of the agreement, WisePlus will serve as the official regional reseller of Wearable Devices' Mudra Technology, allowing WisePlus to demo, negotiate, customize and resell the Company's Mudra Developer Kit which is a comprehensive toolset designed to revolutionize the development and integration on Wearable Devices' neural input technology into solutions, products and services across multiple industries and verticals.

08:47 EDT Vistagen initiates Phase 3 fasedienol trial for SAD treatment - Vistagen announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder SAD . "Initiating Study of Fasedienol for the is another major milestone in our plan to develop and commercialize fasedienol as the first treatment of its kind for social anxiety disorder," said Shawn Singh, Chief Executive Officer. "We look forward to initiating PALISADE-4 in the second half of this year and advancing our innovative pherine pipeline to deliver pioneering neuroscience to patients affected by mental health disorders and unsatisfied with current treatments." PALISADE-3, similar to PALISADE-2, is a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in patients with SAD induced by a public speaking challenge conducted in a clinical setting. ...The U.S. FDA has granted Fast Track designation for the investigation of fasedienol for the acute treatment of SAD.

08:42 EDT Incyte gets payment from CMS Skinhealth for povorcitinib commercialization - Incyte and China Medical System Holdings are pleased to announce that on March 31 Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company or CMS Skinhealth, entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries and a non-exclusive license to manufacture the Product in CMS' Territory. Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS' territory. CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa prurigo nodularis , asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia. "We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options," said Herve Hoppenot, Chief Executive Officer, Incyte. "There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China." Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that, "We expect that this collaboration will enhance CMS Skinhealth's portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China. Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline Ilumetri original/drugs including Hirudoid and Aethoxysklerol in terms of our network and market resources, which will help the Product to realize its clinical and commercial value." The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

08:40 EDT Royalty Management's Environmental Services reports record revenue for March - Royalty Management Holding announced that its environmental services business, under the wholly-owned subsidiary, RMC Environmental Services LLC, has recorded record monthly revenue for the month of March, which equates to a positive cash flow run rate equivalent for all of Royalty Management Holding Corporation. "We are very excited for the success of our growing environmental services business line and the record revenue that those operations achieved in the month of March" stated Thomas Sauve, CEO of RMCO. Mr. Sauve continued, "Hamilton County, Indiana continues to be a rapidly expanding region with a substantial amount of residential, municipal and commercial development. Our business benefits greatly from the need to secure environmental and construction projects and provide management and fill storage for these projects. This revenue has been achieved with very little marketing of our services to the broader community, and with our recent expansion and success, we hope to evaluate ways to further bolster the Company's revenue growth over the course of the next few years, while continuing to minimize the costs of this division. At RMC Environmental Services, we are laser focused on maintaining an extremely low-cost business structure as a whole so that as we further expand revenues, and combined with our other investments and businesses lines, we can commence a consistent dividend policy for our investor base in the near future".

08:37 EDT Incyte, CMS enter collaboration, license agreement for povorcitinib in China - China Medical System and Incyte announced that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company and Incyte entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries and a non-exclusive license to manufacture the Product in CMS' Territory. Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS' territory. CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.

08:36 EDT Virco issues updates investor presentation, preliminary results - Virco Mfg. issued an update of its investor presentation, highlighting the Company's strong recovery following pandemic-related school closures. The investor presentation includes preliminary, unaudited financial results for the Company's Fiscal Year Ended January 31, 2024. As of January 31, 2024, the Company's fiscal year end, Shipments plus Backlog had reached an all-time Company record of $317,604,000. Preliminary, unaudited cash flow and net income for fiscal 2024 also set records not achieved in the last 20 plus years. Virco CEO and Chairman Robert Virtue commented on the Company's strong performance: "During the critical months of the pandemic, when schools were closed, we always retained our focus on eventual recovery. We knew from prior experience that coming out of downturns is often just as difficult as the downturn itself. We made every effort to protect our extraordinary staff and U.S.-based operating assets. We also preserved and actually reinforced our financial strength, allowing us to support school re-opening without the need for additional debt or capital investment. We are pleased to share our success with investors old and new, and especially express our gratitude to those loyal investors who understood our long-term strategy, and supported us through the challenging years of the pandemic. Their support has in turn allowed Virco to support the recovery of America's schools, both public and private, as well as international schools around the world."

08:34 EDT IES Holdings acquires Greiner Industries - IES Holdings announced that it has acquired Greiner Industries. The acquisition also includes the purchase of Greiner's facilities, which cover 450,000-square feet of manufacturing space on a 60-acre campus. Greiner, with 2023 revenue of approximately $58 million, will become part of IES's Infrastructure Solutions segment and continue to operate under the Greiner name. Jeff Gendell, Chairman and Chief Executive Officer, said, "The acquisition of Greiner strategically expands our geographic footprint into the attractive Mid-Atlantic market, while adding several products and services. Greiner, founded by Frank Greiner in 1976, has a long track record of completing large-scale, complex projects and providing specialized industrial services that are highly complementary with our Infrastructure Solutions segment. In addition, Greiner provides an opportunity to further expand the capacity and reach of our existing custom engineered product offerings. I am pleased to welcome Greiner's deep and experienced workforce to the IES family."

08:33 EDT Teva, Launch Therapeutics enter clinical collaboration agreement - Teva (TEVA) and Launch Therapeutics announced a clinical collaboration agreement to further accelerate the clinical research program of Teva's ICS-SABA. Teva and Abingworth, part of global investment firm Carlyle (CG), also announced a strategic development funding agreement in which Abingworth provides Teva up to $150M to offset Teva's ICS/SABA program costs. As part of the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, will have the lead role in the operational execution and management of the planned clinical trials, focused on accelerating Teva's ICS-SABA clinical research program. Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. If TEV-'248 receives U.S. FDA regulatory approval, Abingworth will be eligible to receive fixed payments as well as success payments based on ICS/SABA sales. Teva will recognize the funding as a reduction in research and development expenses and will retain full rights to the company's ICS/SABA program. Teva's TEV-'248 has potential to be the first ICS/SABA for both adult and pediatric indications, combining fluticasone propionate and albuterol sulfate delivered via Teva's breath-activated, multi-dose dry powder inhaler, which is used with other approved medicines in Teva's respiratory product portfolio.

08:32 EDT Lightwave Logic awarded new patent - Lightwave Logic announced the issuance of patent 11,921,401 by the United States Patent and Trademark Office entitled 'Nonlinear Optical Chromophores Having a Diamondoid Group Attached Thereto, Methods of Preparing the Same, and Uses Thereof' issued on March 5, 2024, which has been shown to significantly improve the overall stability and performance of the company's EO chromophores.

08:31 EDT Nexa Resources to offer senior unsecured notes - Nexa Resources announced its plan to offer new senior unsecured notes guaranteed by Nexa Resources Cajamarquilla S.A. and Nexa Recursos Minerais. Nexa aims to use the net proceeds from the offering primarily to fund a cash tender offer for its existing notes due 2027 and notes due 2028 that are validly tendered and accepted for purchase pursuant to tender offers announced today, and the remainder, if any, for general corporate purposes, including liability management transactions. The notes will be unsecured obligations of Nexa and will be fully and unconditionally guaranteed by the Guarantors. The guarantees will rank equally in right of payment with all of the Guarantors' other unsecured and unsubordinated debt obligations.

08:25 EDT Smith-Midland Corp announces delayed filing of 2023 Form 10-K - Smith-Midland has filed a Form 12b-25 with the Securities and Exchange Commission to provide notice of the late filing of its Annual Report on Form 10-K for the year ended December 31, 2023. The company expects to file its Form 10-K on or before April 16, 2024. The extension is related to the Company requiring additional time to complete its financial reporting close process, including management's assessment of the Company's internal control over financial reporting, as to which material deficiency existence will be made, and to gather information required to complete auditing procedures. As previously reported throughout 2023, revenue is expected to be higher for the year ended December 31, 2023 than the prior year ended December 31, 2022 resulting in higher net income for the year ended December 31, 2023 than the prior year ended December 31, 2022.

08:24 EDT Vislink reports Q4 EPS (99c) vs ($2.36) last year - Reports Q4 revenue $8.1M vs $7.4M last year. "2023 marked a pivotal year for Vislink, as we laid the groundwork for accelerated revenue growth and cash flow neutrality in 2024," said Vislink CEO Mickey Miller. "During the year, we significantly advanced our presence in the expanding AVDS market, as evidenced by a 75% year-over-year revenue growth in the MilGov space. In September, we finalized the strategic acquisition of BMS assets, marking a significant step forward in expanding our reach within the MilGov market, especially in EMEA. This move has quickly demonstrated its value, as evidenced by a substantial order we've recently secured in the region. BMS's customer base complements our AVDS solutions perfectly, significantly broadening our market reach and growth potential in the coming years. Additionally, the launch of Air-to-Anywhere in our AVDS platform, which integrates AI for advanced analytics, has opened new avenues for developing recurring revenue by offering in-depth data insights to customers. This milestone is part of a broader success story, as we also saw our high-margin software and services revenue climb above 10% of total revenue in 2023, exceeding our goal set at the beginning of the year."

08:22 EDT AlTi Global acquires East End Advisors for $76M - AlTi Global announced the acquisition of East End Advisors, an independent advisory firm with assets under management, or AUM, of approximately $5.6B, offering customized portfolio management and investment services to a select group of UHNW families and foundations. This follows the recently announced strategic investment in AlTi of up to $450M from Allianz X, an investment arm of Allianz SE, and Constellation Wealth Capital, an investment advisory firm specializing in making investments in wealth managers. The capital will be used to accelerate AlTi's strategy to become the leading global independent wealth management platform for the UHNW segment, with targeted expertise in alternatives. Headquartered in New York, East End's investment record and experienced team expand AlTi Tiedemann Global's operations in key regions within the U.S. AlTi is acquiring East End Advisors for an initial purchase price of approximately $76M. An additional contingent consideration will be payable over a five-year period, calculated in accordance with an EBITDA-based formula. A certain portion of the contingent consideration is required to be paid in cash based on certain minimum annual thresholds, and the balance may be settled in cash or Class A Common Stock, at AlTi's discretion. The initial purchase price is expected to be funded by the previously announced investment from Constellation Wealth Capital. The transaction is subject to customary closing conditions and is expected to close early in the second quarter.

08:21 EDT Applied Digital issues $50M unsecured convertible debenture - Applied Digital entered into a private financing agreement with a single investor, in which it issued a $50 million unsecured convertible debenture. The convertible debenture bears no interest, has an original issue discount of five percent and has a term of 54 weeks. The conversion price for the note is the lower $6.00 and 95% of the lowest daily volume weighted average price of the Company's common stock during the five trading days immediately prior to the date of conversion, subject to a floor price of $3.00, except that the Investor may, at its option, elect to use the $6.00 fixed conversion price. The Investor is limited to converting no more than $9.0 million per month, and may only begin to convert after May 1, 2024, except that these limitations do not apply if there's an event of default and the conversion price is set at $6.00. Subject to the Investor's right to convert, the Company may prepay the note at any time that the Company's common stock trades below $6.00 or the tenth trading day after the registration statement registering the resale of the note's underlying shares becomes effective. The Investor has contractually agreed not to short the stock during the term of the note. Northland Capital Markets acted as advisor and sole placement agent for the Company on the financing. Lowenstein Sandler LLP acted as legal counsel to the Company.

08:19 EDT ASP Isotopes enters into purchase agreement with leading semiconductor company - ASP Isotopes announced that it has entered into a purchase agreement with an industry leader in the design and manufacturing of semiconductors. Under the terms of the agreement, ASP Isotopes expects to supply highly enriched silicon-28 to the customer for use in next-generation semiconductors. The product is expected to be supplied from the Company's South African production facility and shipped to the customer in the USA during 2024. "To create faster, smaller next-generation semiconductors, the world is likely going to require materials that are currently not available in commercial quantities," said Paul Mann, ASP Isotopes' Chairman and Chief Executive Officer. "ASP Isotopes is currently working on many isotopically pure elements that we believe will help semiconductor companies create the chips that the world will require in the future to enable technologies such as Quantum Computing and Artificial Intelligence."

08:18 EDT Sealsq selected by D-Link to deliver compliant node attestation certificates - SEALSQ Corp announced that its PKI-as-a-Service solution "INeS" has been selected by D-Link, a global leader in networking solutions, to provide Node Attestation Certificates for D-Link's MS30-N, MS30, and MS60-I Matter-compliant IoT Gateways. "SEALSQ's INeS platform enables D-Link MS30-N, MS30, and MS60 IoT gateways to offer features like faster connection to a Matter ecosystem for the devices they manufacture. Additionally, it provides higher flexibility for D-Link to manage certificates at design and manufacturing stages," said Frank Buonnano, VP of Global Sales for SEALSQ. He added, "The combination of D-Link product technology and SEALSQ's PKI services provides consumer and businesses with ready-to-use Matter-trusted products. D-Link's networking and connectivity products are distributed to consumers, small businesses, medium to large-sized enterprises in 43 countries."

08:17 EDT Brown-Forman to launch distribution business in Japan - Brown-Forman is launching its own distribution business in Japan, bringing the distribution in-house for the first time since the company entered the market in the 1970s. The new Brown-Forman Japan office opened in the city center of Tokyo at the end of 2023.

08:16 EDT Annovis Bio announces publication on buntanetap - Annovis Bio announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein in patients with early Alzheimer's Disease. In this randomized, double-blind, placebo-controlled study, participants received oral buntanetap up to a 25-day period. At the end of the study, patients were catharized in the lumbar spine for 36 hours to accommodate the total time it takes for APP to be synthesized, processed into Abeta, and degraded. Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug's safety and tolerability. Furthermore, multiparameter modeling of APP kinetics provided additional evidence for dose-dependent lowering of APP production by buntanetap. A model that included the pre-drug lumbar CSF concentration as a covariate showed statistical significance between the placebo and 120, 180 mg per day buntanetap groups, suggesting a drug effect on lowering APP production. In general, buntanetap lowered the rate of translation, the maximum concentration, lengthened the Tmax, and decreased the area under the curve.

08:16 EDT Natera launches Alliance A032103 utilizing Signatera MRD test for MIUC - Natera announced the launch of Alliance A032103 MODERN , a randomized, phase II/III, biomarker-integrated trial. Alliance A032103 MODERN will utilize Signatera , Natera's personalized and tumor-informed molecular residual disease MRD test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer MIUC after radical cystectomy. "The MODERN trial represents a step towards precision medicine in bladder cancer treatment," said Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute. "By using Signatera to measure residual cancer after surgery, the Alliance A032103 (MODERN) trial may ultimately help to tailor the use of immunotherapy after surgery and optimize the care of individual patients." "MODERN, like the CIRCULATE clinical trials in colorectal cancer, is a pivotal study that examines how Signatera-guided escalation and de-escalation pathways can potentially improve patient outcomes," said Minetta Liu, MD, chief medical officer of oncology at Natera. "We are grateful to collaborate with the Alliance on this important study."

08:15 EDT Aemetis implements Microsoft Dynamics ERP system - Aemetis (AMTX) announced the design, installation and implementation of the Microsoft (MSFT) Dynamics enterprise resource planning system worldwide for all Aemetis operations in the U.S. and India to support current operations and expansion projects. The tools and processes required to operate a global company, including manufacturing, supply chain, finance and accounting, are included in the Microsoft Dynamics ERP system. "The Microsoft DynamicsTM ERP system was selected after an extensive process of evaluating our evolving needs due to the rapid growth of the company," stated Todd Waltz, Chief Financial Officer of Aemetis, Inc. "The specific requirements of our project management, construction and operations are supported by the new ERP system, as well as providing theplatform for the strong internal control system necessary to support the accounting and reporting requirements of ourbusiness and capital market initiatives."

08:14 EDT Disc Medicine announces Phase 2 AURORA study met primary endpoint - Disc Medicine presented topline data from AURORA, a phase 2 study of bitopertin in patients with EPP. Treatment with bitopertin resulted in statistically significant reductions in PPIX, the primary endpoint, and significant improvements in the rate of phototoxic reactions with pain and the Patient Global Impression of Change. It met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groups. On the key secondary endpoint of cumulative time in sunlight on days without pain, bitopertin patients had a positive response consistent with BEACON results, but the endpoint did not meet statistical significance due to strong placebo performance. "This study has confirmed that bitopertin significantly reduces the toxic metabolite, PPIX, in patients with EPP, and we have shown that bitopertin-treated patients experience improvements in the clinically meaningful outcomes of Patient Global Impression of Change and the number and rate of phototoxic reactions with pain, with the 60 mg dose reaching statistical significance compared to placebo. Despite the strong performance of bitopertin on the key secondary endpoint of cumulative time in light, consistent with results seen in BEACON, statistical significance was not met due to an outsized placebo response," said John Quisel, J.D., Ph.D., President and Chief Executive Officer. "Given that, we will need to conduct an analysis of our final data set and work with investigators, regulators, and patient advocacy groups to define the optimal registrational endpoints moving forward. While we do this additional work, we continue to be excited about the upcoming readouts from our other programs, including updated data from our DISC-0974 study in anemia of myelofibrosis in Q2."

08:12 EDT Mullen Automotive files for FTZ status in Tunica, Mississippi - Mullen Automotive the Company has filed for Foreign Trade Zone, FTZ, status with the U.S. Department of Commerce at its commercial vehicle manufacturing and assembly center located in Tunica, Mississippi. Mullen filed its application on March 25, 2024, and expects final determination within 30 to 90 days. Upon approval as a designated FTZ site, Mullen would qualify for a variety of benefits including deferment of payments on duties owed related to import fees. With FTZ approval the Company would be able to align duty payment to vehicles sold so the pressure on cash flow would be dramatically inverted from the current model of paying duty at time of import. Upon approval, Mullen estimates that resulting deferred working capital on domestic sales could result in deferred capital outlays of $10 million for the remainder of FY 2024.

08:12 EDT ZimVie estimates cash of $66M as of April 2 - As previously communicated, ZimVie expects to achieve an annualized financial profile of $455+ million in Net Sales, and a 15%+ adjusted EBITDA margin one year following the close of the deal. ZimVie intends to immediately pay down $275 million of outstanding debt, leaving total debt of approximately $234 million, and estimated cash of approximately $66 million as of April 2, 2024.

08:10 EDT Kratos Defense, Shield AI conduct AI-powered flights on Kratos tactical firejet - Kratos Defense & Security Solutions announced the successful completion of the first phase of Shield's AI-piloted flight-testing on-board the Kratos family of UAS as the two companies move toward productizing Shield AI's pilot on these systems. "Our substantial investments in autonomy and AI design tools, infrastructure, and pipelines are what enable Shield AI to rapidly integrate Hivemind onto different classes of aircraft and most importantly, fly them safely. We're getting faster and faster. It was over three years from signing the contract to flying the F-16; now, it's less than 180 days for the Kratos Firejet. The vision of portable autonomy software for military hardware has been realized, flown, and deployed by Shield AI," said Ryan Tseng, Shield AI's CEO and Co-Founder.

08:10 EDT Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial - Vertex Pharmaceuticals announced that inaxaplin has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease, or AMKD, where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD. In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years. Previously reported Phase 2a proof-of-concept data demonstrated that inaxaplin led to a statistically significant and clinically meaningful mean reduction in the urine protein to creatinine ratio of 47.6% at 13 weeks of treatment compared to baseline, providing the first clinical evidence that an oral small molecule APOL1 inhibitor can decrease proteinuria in people with AMKD. An Independent Data Monitoring Committee, or IDMC, reviewed blinded and unblinded Phase 2 safety and efficacy data from the Phase 2/3 pivotal trial, which evaluated two different doses of inaxaplin compared to placebo for 12 weeks of treatment in patients ages 18 to 65 years and recommended the selection of a single inaxaplin dose of 45 mg once daily in the Phase 3 portion of the Phase 2/3 study. The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study. The FDA has granted inaxaplin Rare Pediatric Disease Designation and Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis. The European Medicines Agency has also granted inaxaplin Priority Medicines and Orphan Drug designations for AMKD.

08:09 EDT Smith & Nephew introduces RENASYS EDGE NPWT System - Smith+Nephew announced the launch of its RENASYS EDGE Negative Pressure Wound Therapy System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn, it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients' daily activities. Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System - SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this new, innovative technology to more patients on a national level and support its growing negative pressure wound therapy business.

08:08 EDT AdTheorent to be acquired by Cadent for $3.21 per share - AdTheorent Holding Company and Cadent announced that they have entered into a definitive agreement under which a wholly owned subsidiary of Cadent will acquire the Company in an all-cash transaction. Upon closing of the transaction, AdTheorent will become a privately held company. Under the terms of the definitive merger agreement, which has been unanimously approved by AdTheorent's Board of Directors. the Company's common stockholders will receive cash consideration of $3.21 per share. The transaction represents an equity value for the Company of approximately $324 million and represents a 17% premium to the 60-day volume weighted average stock price as of March 28, 2024 and a 27% premium to the 90-day volume weighted average stock price as of March 28, 2024. The definitive merger agreement also includes a 33-day "go shop" period that will allow the Company to affirmatively solicit alternative proposals from interested parties. The transaction is expected to be completed by the third quarter of 2024 and is subject to approval by AdTheorent's stockholders, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as well as other customary closing conditions. Upon completion of the transaction, AdTheorent common stock will no longer be listed on the Nasdaq Stock Exchange or trade in any other public market. Fully committed debt financing in support of the transaction is being provided by Royal Bank of Canada. The transaction is not subject to a financing condition.The definitive merger agreement includes a 33-day "go-shop" period that will expire at 11:59 PM ET on May 4, 2024, which permits AdTheorent and its financial advisor to actively solicit and consider alternative acquisition proposals. There can be no assurance that this process will result in a superior proposal, and the Company does not intend to disclose developments with respect to the "go-shop" process unless and until it determines such disclosure is appropriate or is otherwise required. H.I.G. Growth Partners, LLC and its affiliated investors, along with members of the AdTheorent Board and management who together own or control approximately 40% of the Company's outstanding shares, have each entered into a voting and support agreement pursuant to which they have agreed, among other things, to vote their respective shares of AdTheorent common stock in favor of the transaction.

08:07 EDT Cingulate reports Q4 EPS net loss $6.9M - As of December 31, 2023, Cingulate had $52,416 in cash and cash equivalents. "I am pleased to report that Cingulate is stronger today than the end of last year," said Shane J. Schaffer, Chairman and CEO of Cingulate Inc. "With the addition of three independent directors, each of whom possess deep experience in the pharmaceutical industry, small-cap publicly traded companies, and hold executive leadership roles within pharma, the Cingulate board is equipped to overcome the challenges ahead."

08:06 EDT Cadent to acquire AdTheorent for cash consideration of $3.21 per share - Cadent announced a definitive agreement to acquire all outstanding shares of AdTheorent Holding Company for a cash consideration of $3.21 per share. The transaction is subject to customary closing conditions and completion of regulatory review and AdTheorent shareholder approval. The transaction has been approved by the AdTheorent Board of Directors and is expected to close in approximately 90 days.

08:04 EDT Novavax reports data on updated COVID-19 vaccine - Novavax will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination vaccine candidates at the World Vaccine Congress 2024 in Washington, DC, April 2 to 4, 2024. New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant. Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine. Differences observed in immunoglobulin (IgG) subclass responses and Fcgamma-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared. Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.

07:51 EDT Medigus announces installation of wireless charging system for car parks - Medigus announced an achievement by its subsidiary, Charging Robotics, which has completed the installation of its wireless charging system for an automated parking system. The installation, previously announced, was in an automatic car park facility in Tel Aviv, Israel together with the provider of this facility under a pilot project intended to verify the performance of the system. The system reaches a charging power of 10kW and includes managed charging capabilities to meet a limited supply of electricity and prioritize the charging process. The system includes a user interface installed on the driver's smart phone, which is used to operate the system, receive updates on the charging process, generate billing reports and other useful information.

07:46 EDT Bombardier announces start date of new NCIB - Bombardier confirmed that its new normal course issuer bid will commence on April 3, 2024, following the early termination of its current normal course issuer bid. The Toronto Stock Exchange has approved purchases, from April 3, 2024 to April 2, 2025, up to 1,750,000 of its Class B shares under the New NCIB, representing approximately 2.05% of the 85,307,628 Class B shares issued and outstanding as of March 21, 2024. The Corporation's current normal course issuer bid commenced on May 23, 2023 for a 12-month period that would have ended May 22, 2024 for a maximum of 600,000 Class B shares. The maximum amount of shares under the 2023 NCIB have been purchased. As permitted by the TSX, the 2023 NCIB will terminate early on April 2, 2024, the day prior to the effective date of the New NCIB.

07:42 EDT Ebix reports conclusion of SEC investigation, dismissal of securities claims - Ebix announced that the Securities and Exchange Commission has concluded its investigation of Ebix and officially communicated that it does not intend to recommend an enforcement action by the SEC against Ebix. This non-public investigation was carried out by the SEC in response to the RSM resignation and the subsequent Hindenburg short report. In another event, Ebix also announced that it has won the Second Circuit appeal in the United States District Court for the Southern District of New York, with all the pending securities fraud claims against Ebix and its officers, filed in the SDNY being dismissed with prejudice and the dismissal affirmed on appeal. This class action suit - Ebix vs. Rahul Saraf, was filed in the SDNY after the RSM resignation and the subsequent Hindenburg short report.

07:39 EDT Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints - Zai Lab Limited (ZLAB) partner Bristol Myers Squibb (BMY) announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI or adagrasib as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer NSCLC harboring a KRASG12C mutation, met the primary endpoint of progression-free survival PFS and the key secondary endpoint of overall response rate ORR as assessed by Blinded Independent Central Review at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard of-care chemotherapy as a second-line or later treatment for these patients. KRAZATI had no new safety signals and the safety data was consistent with the known safety profile. "We are delighted to see these data underscoring the potential of adagrasib as a therapy for patients with KRASG12C mutated NSCLC in second or later line treatment," said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab. "Lung cancer is the most common cancer in China, and adagrasib is one of several important products in Zai Lab's growing lung cancer pipeline. We are proud to have contributed to the KRYSTAL-12 study and are looking forward to bringing adagrasib to patients in need in China." Bristol Myers Squibb will complete a full evaluation of the available data and will share the results with the scientific community at an upcoming medical conference as well as discuss the results with health authorities. Zai Lab expects to submit the New Drug Application NDA for adagrasib to the National Medical Products Association NMPA for KRASG12C mutated NSCLC in second or later line treatment in China this year.

07:35 EDT Ondas expects to generate 'significant' revenue growth for 2024 - The Company expects to generate significant revenue growth for the full year 2024 driven by growing customer activity in both business units with orders and backlog increasing throughout the year. Bookings and revenue growth are expected to fluctuate from quarter-to-quarter given the uncertainty around the timing of customer activity in front of the targeted commercial rollout for the 900 MHz Rail network, the development programs underway with Siemens and MxV Rail, in addition to the timing of OAS's deliveries to the UAE and its growing roster of customers in the United States.

07:33 EDT Nouveau Monde pays accrued interests as part of November 8 private placement - Nouveau Monde Graphite announces payment of accrued interests as part of a previously announced private placement announced by press release dated November 8. Settlement of Accrued Interests Upon the approval of the TSX Venture Exchange and the New York Stock Exchange the accrued interests owed to Investissement Quebec for the first quarter of 2024 under the unsecured convertible note, as amended and restated, ssued in connection with 2022 Private Placement, will be deemed paid. 141,786 common shares at a price of $2.30 representing an aggregate amount of $326,108 will be issued and share certificates will be delivered to the Holder at the maturity, conversion, or redemption of the Note in payment of the accrued interests due on March 31 for the first quarter of the year. The issuance of Common Shares is subject to the approval of the Exchanges and, when issued, will be subject to a hold period of fou months and one day. In connection with NMG's private placements announcement on February 15 interest under the unsecured convertible notes issued by NMG to Mitsui and Pallinghurst Bond Limited, respectively, has ceased to accrue as of February 14.

07:32 EDT Context Therapeutics submits IND application for CTIM-76 - Context Therapeutics announced that on March 28, 2024, the Company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6-positive gynecologic and testicular cancers.

07:23 EDT Nutriband begins manufacturing for Fit For Life Group - Nutriband has been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband's wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer.

07:20 EDT Laser Photonics postpones Q4, 2023 earnings release - Laser Photonics will postpone reporting its fourth quarter and full-year 2023 ended December 31, 2023, as it is still in the final stages of completing its audit. As a result, the Company is canceling its webcast and conference call to discuss results that was scheduled to take place on April 1, 2024. The Company intends to notify investors via press release when it is able to determine a date to report its fourth quarter and full-year 2023 numbers and reschedule its conference call to discuss these results

07:18 EDT Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve - Sol-Gel Technologies (SLGL) announced that Padagis Israel Pharmaceuticals, Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application, ANDA, to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older. On March 26, 2024, Arcutis Biotherapeutics, Inc. (ARQT) initiated a patent infringement action in the U.S. District Court for the District of New Jersey regarding the Padagis Roflumilast Cream, 0.3% ANDA. "According to recent leading analysts' reports, Zoryve Cream is estimated to generate net revenue exceeding $500 million by the end of 2030. Submissions such as Padagis's Roflumilast Cream, 0.3% ANDA demonstrate the historic value of Sol-Gel's partnership with Padagis. Though Sol-Gel exited the majority of the partnership in the generic divestment deal announced on November 4, 2021, the Roflumilast Cream, 0.3% project was maintained because of the potential value to both companies," stated Mr. Mori Arkin, Executive Chairman of the Board of Sol-Gel.

07:16 EDT Ocuphire Pharma announces U.S. commercial launch of RYZUMVI - Ocuphire Pharma (OCUP) announced the U.S. commercial launch of RYZUMVI by its partner Viatris (VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.

07:15 EDT Telesat Holdings, Government of Canada agree to terms on C$2.14B loan - Telesat announced that on March 28, 2024, Telesat received a letter from Canada's Minister of Innovation, Science and Industry regarding an investment in Telesat Lightspeed. The letter states that, following several months of negotiations between Telesat and federal officials, the Government of Canada is prepared to invest C$2.14 billion in Telesat Lightspeed by way of a loan to Telesat LEO, a wholly owned subsidiary of Telesat, that is developing and will own and operate the highly advanced Telesat Lightspeed Low Earth Orbit global broadband satellite constellation. "Telesat Lightspeed is a highly innovative and disruptive global broadband network and the largest space program in Canada's long and distinguished history as a space faring nation," said Dan Goldberg, Telesat's President and CEO. "I am delighted with the engagement we have had with the Government of Canada on this flagship program, which will help bridge the global digital divide, create and sustain thousands of high-quality jobs in Canada, spur domestic innovation, investment and exports, and ensure that Canada is at the forefront of the rapidly growing New Space Economy. The Government of Canada has been a strong supporter of the Telesat Lightspeed program and we applaud their leadership and foresight."

07:14 EDT Enthusiast Gaming announces C$4.1M sale of select non-core assets - Enthusiast Gaming Holdings has entered into a definitive agreement for the divestment of certain non-core and non-profitable casual gaming assets for a purchase price of approximately C$4.1 million. The Assets comprise a subset of Enthusiast Gaming's casual gaming business, and the divestment is a continuation of a number of recent strategic actions designed to enhance the Company's operational efficiency while emphasizing high-margin revenue growth and sustainable profitability. Other recent actions include a C$10 million cost reduction program, and a multi-year partnership with Playwire to improve programmatic yield and unlock additional revenue streams, both actioned in March. The Asset Sale Agreement is expected to close in 10 business days and is subject to customary closing conditions.

07:13 EDT Ellington Residential to focus on CLOs, revoke REIT election - Ellington Residential announced that its board of trustees has unanimously approved a strategic transformation of its investment strategy to focus on corporate collateralized loan obligations, or CLOs. The company intends to build upon its current $44M CLO portfolio, with an emphasis on secondary CLO mezzanine debt and equity tranches. In connection with its strategic transformation, the company has decided to revoke its REIT election for tax year 2024. Later this year, the company intends to convert to a registered closed end fund to be treated as a regulated investment company and, in the meantime, will operate as a taxable C-Corp and plans to take advantage of its significant existing net operating loss carryforwards to offset the majority of its U.S. federal taxable income. The company intends to complete all necessary steps for the closed end fund/RIC conversion later this year, subject to receiving shareholder approval of certain matters. In light of the strategic transformation, the company will reschedule its 2024 annual meeting of shareholders.

07:12 EDT Bitfarms mined 286 bitcoin in March - March 2024 Select Operating Highlights: 6.5 EH/s online at March 31, 2024, up 35% Y/Y and unchanged from previous month. 5.7 EH/s average online, down 6.6% from the previous month. 50 BTC/average EH/s, up 2.0% from the previous month. 286 BTC earned, 5% lower than previous month and 33% lower Y/Y. 9.2 BTC earned daily on average, equal to ~$647,700 per day based on a BTC price of $70,400 at March 31, 2024. 1,656 Bitmain T21 miners received with majority online. Geoff Morphy, President and Chief Executive Officer said, "In March, we exercised our previously announced purchase option for 28,000 Bitmain T21 miners and purchased an additional 19,280 Bitmain T21 miners along with 3,888 Bitmain S21 miners and 740 Bitmain S21 hydro miners. Having confirmed the tremendous performance of our T21 miners currently running, and with Bitcoin prices reaching all-time highs, we acted quickly to secure these miners at attractive prices in advance of anticipated hardware price increases. Together, with our 35,888 Bitmain T21 purchases and farm expansions announced in November, these new 87,796 miners are sufficient to reach 21 EH/s by year-end, with greater operating efficiency."

07:11 EDT Digihost mines 91 bitcoin during March - Monthly Production Highlights for March 2024: The Company held cash, BTC and cash deposits of approximately $6.2 million as of March 31, 2024, as compared to $3.9 million as of January 31, 2024, representing an increase over the previous month of approximately 60%. The increase in the Company's ending cash, BTC, and cash deposits position over the previous month is partially due to the execution of a multi-year hosting agreement with one of the world's leading manufacturers of digital currency mining servers that it announced on March 5, 2024. Under the executed agreement, Digihost received an upfront deposit along with 4,640 S19 XPs, which equates to approximately 14MW of hosting. The Company plans to deploy these next generation, highly energy efficient and high-performance miners prior to the next Bitcoin halving. The deployment will result in an expected hash rate increase of approximately 700 PH/s, bringing Digihost's total hash rate to 2.4 EH/s. Mined approximately 91 BTC during the month of March, representing a decrease of Daily BTC mined during the month decrease of 2% compared to February 2024, as overall BTC difficulty increased by approximately 5% during the month due to the continued rise in prices of certain cryptocurrencies during the month of March. Despite the increase in mining difficulty, the Company's ending BTC position increased over the previous month by approximately $1.4 million. During the period, the Company paid off in the full the remaining balance owed on a BTC loan payable. Spent approximately $0.2 million on capital expenditures and mining infrastructure support equipment. Digihost continues to monitor its capital expenditures closely with self-funding to limit equity dilution for its shareholders. Consistent with management's ongoing commitment to minimize equity dilution for its shareholders, the Company has continued to monetize a portion of its BTC production to fully fund its energy costs. Presently, Digihost's consolidated operating capacity across its three sites represents approximately 90MW of available power and is mining at hashrate of 2 EH/s.

07:07 EDT Guess announces new $200M share repurchase program - Guess announced that its board of directors has authorized a new share repurchase program of up to $200M of the company's common stock. Guess also separately announced today that, as part of this new program and through a convertible bond exchange transaction, it has agreed to repurchase 326,429 shares of the company's common stock for $10.3M.

07:07 EDT Trian says institutional investors express support for candidates at Disney - The Trian Group, which beneficially owns over $3.5B of common stock in The Walt Disney Company, announced that two respected institutional investors, the California Public Employees' Retirement System and Neuberger Berman, a global asset manager, have expressed their support for both of Trian's nominees, Nelson Peltz and Jay Rasulo, in connection with Disney's annual meeting, which is scheduled to be held this Wednesday, April 3, 2024. Both CalPERS and Neuberger Berman recognize Disney's poor track record of corporate governance - which includes a persistent and significant lack of alignment between pay and performance and a failure to appropriately manage CEO succession - noting that the Disney Board would benefit from "a fresh perspective" and "[t]wo new directors who are qualified and capable of leading needed change..." In supporting the election of Nelson Peltz and Jay Rasulo, CalPERS noted the following: "CalPERS believes Walt Disney Co will benefit from fresh eyes on its board of directors and voted its company shares in favor of candidates Nelson Peltz and Jay Rasulo...[CalPERS'] established voting guidelines focus on the need for independent corporate boards, a say in setting executive pay, and increased transparency. Two new directors who are qualified and capable of leading needed change in corporate governance will serve the Disney board well." Similarly, Neuberger Berman wrote that: "We believe there is opportunity to strengthen relevant policies and practices and that the board may benefit from the addition of a fresh perspective and more independence. For these reasons, we intend to support the election of dissident Trian nominees Nelson Peltz and James Rasulo to the board....[W]e believe [Trian's] nominees are very strong candidates given Peltz's large ownership of the company and extensive board experience and Rasulo's long-term experience while working as an executive at Disney...W]e do not believe short-term TSR performance alone is an adequate indicator of the quality of governance at a company. Despite recent improvements, in our opinion, the deficiencies of the board that ultimately led to the failed 2020 succession endeavor and related consequences remain. As such, we are unconvinced of the current board's ability to uphold good governance practices and fulfill one of its core responsibilities in finding a CEO successor...[W]e have concerns regarding the Disney board's multi-year efforts to name a successor to CEO Bob Iger...The board has admitted to not adhering to and executing the process it had in place for Disney's 2020 succession plan and that Chapek's appointment was a strategic misstep...[W]e believe these succession planning challenges have impacted business continuity and distracted from business performance.

07:05 EDT Viatris announces U.S. commercial launch of Ryzumvi - Viatris announced the U.S. commercial launch of Ryzumvi 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents in the United States. Ryzumvi is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.

07:04 EDT 3M finalizes settlement with public water suppliers - 3M announced the company's previously announced settlement agreement with U.S. public water suppliers, or PWS, received final approval from the U.S. District Court in Charleston, South Carolina. The now-finalized agreement will support PWS that detect PFAS at any level or may do so in the future and will benefit U.S.-based PWS that provide drinking water to Americans across the country. The agreement received overwhelming support and participation from U.S. PWS, and the court resolved the small number of objections that were raised in favor of the settlement. As previously disclosed, 3M recorded an accrual of $10.3B for this matter, which reflects the pre-tax present value of the expected payments over 13 years under the agreement. Payments under the agreement are scheduled to begin in the third quarter of 2024, provided there are no pending appeals of the final approval order. 3M also continues to actively engage in insurance recovery activities.

06:56 EDT Aecom awarded NASA contract - AECOM announced that it has been selected by the National Aeronautics and Space Administration to provide environmental restoration and compliance services at facilities across the United States as part of the NASA Environmental Restoration and Compliance Contract. Under this five-year contract, AECOM will provide support for environmental restoration activities, including environmental sampling; investigations of potential environmental contaminants; human, health, and ecological risk assessments; and remediation activities. The NERCC will also serve as the primary contracting vehicle for NASA's PFAS-related investigation and remediation efforts. With more than two decades of PFAS experience at more than 500 sites globally, AECOM is well positioned to support NASA's PFAS initiatives. The company will also provide compliance and sustainability related services across NASA facilities that include pollution prevention, recycling and hazardous materials management.

06:12 EDT Aurora Mobile signsstrategic agreement with Beijing Moonshot AI Technology Co. - Aurora Mobile announced that it has signed a strategic agreement with Beijing Moonshot AI Technology Co., an artificial general intelligence company in China, to provide intelligent messaging services and verification services for Moonshot AI's smart assistant app Kimi. The partnership reflects Moonshot AI's high recognition of Aurora Mobile's robust and highly reliable technical capabilities and services. Both companies have high expectations and strong confidence that this cooperation will create further opportunities in the field of AGI.

06:04 EDT Townsquare Media repurchases approximately 10% of outstanding shares - Townsquare Media announced that it is repurchasing and retiring 1.5 million shares of Class A common stock held by MSG National Properties for $9.76 per share. The purchase price reflects an 11% discount from the closing price of the Class A common stock on March 28, 2024. This transaction follows Townsquare's June 2023 repurchase of 1.5 million shares from MSG at $9.70 per share, and March 2021 repurchase of 12.6 million shares and warrants from Oaktree Capital Management, L.P. at $6.40 per share. The purchase price of $14.6 million was funded entirely with cash on hand. In 2023, Townsquare's Cash Flow from Operations increased 35% year-over-year to $68 million, or approximately $4.07 per basic share based on shares outstanding as of March 28, 2024. Pro forma for this transaction, Cash Flow from Operations per basic share increased to approximately $4.47, representing accretion of approximately 10%. Following the transaction, the company has 15.2 million shares outstanding.

06:01 EDT UPS awarded significant air cargo contract by USPS - UPS announced the company has been awarded a significant air cargo contract by the United Stated Postal Service. This award is effective immediately and greatly expands the existing relationship between the two organizations. Following a transition period, UPS will become the USPS's primary air cargo provider and move the majority of USPS air cargo in the US.

05:37 EDT Nio delivers 11,866 vehicles in March - Nio announced its March and first quarter 2024 delivery results. Nio delivered 11,866 vehicles in March, increasing by 14.3% year-over-year. The deliveries consisted of 6,737 premium smart electric SUVs, and 5,129 premium smart electric sedans. Nio delivered 30,053 vehicles in the first quarter of 2024. Cumulative deliveries of Nio vehicles reached 479,647 as of March 31.

05:09 EDT Li Auto delivers 28,984 vehicles in March - Li Auto announced that the company delivered 28,984 vehicles in March, increasing by 39.2% year over year. This brought the company's first-quarter deliveries to 80,400, up 52.9% year over year. The cumulative deliveries of Li Auto vehicles reached 713,764 as of the end of March, establishing Li Auto as the first Chinese emerging new energy automaker to reach a milestone of 700,000 cumulative deliveries.